SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

NCT02580305 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

564

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: SUVN-502
DRUG: Placebo
DRUG: Donepezil
DRUG: Memantine

Sponsor

Suven Life Sciences Limited